Compare KMT & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | RCUS |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1994 | 2018 |
| Metric | KMT | RCUS |
|---|---|---|
| Price | $38.78 | $22.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $36.00 | $30.27 |
| AVG Volume (30 Days) | ★ 1.0M | 856.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,966,845,000.00 | $247,000,000.00 |
| Revenue This Year | $13.94 | N/A |
| Revenue Next Year | $7.27 | $83.23 |
| P/E Ratio | $52.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.62 | $7.06 |
| 52 Week High | $42.03 | $26.40 |
| Indicator | KMT | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 51.85 |
| Support Level | $37.93 | $20.18 |
| Resistance Level | $41.89 | $24.33 |
| Average True Range (ATR) | 1.23 | 1.09 |
| MACD | 0.37 | 0.11 |
| Stochastic Oscillator | 85.17 | 66.52 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.